Prevalence and correlates of HCV infection among methadone maintenance attendees: Implications for HCV treatment

International Journal of Drug Policy

Volumn 15, Issue 2, 2004, Pages 93-101

  Loughlin, Anita M ^a   Schwartz, Robert ^b   Strathdee, Steffanie A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Open Society Institute Baltimore   (United States)

Author keywords

Co morbidity; Drug users; Hepatitis C; Methadone; Prevalence; Treatment

Indexed keywords

HEPATITIS B VACCINE; METHADONE;

ADULT; AGED; ARTICLE; ASSOCIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; FEMALE; HEALTH INSURANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; INCOME; INJECTION; LABORATORY TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENTAL HEALTH; METHADONE TREATMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SOCIAL CLASS; UNITED STATES;

EID: 1642351004     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2003.10.005     Document Type: Article

References (47)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A.et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine. 341(8):1999;556-562.
2. Antela A., Casado J.L., Gonalez M.J., Perez P., Perez-Elias M.J., Montilla P.et al. Influence of a methadone maintenance programme on the improved outcome of a cohort of injecting drug users with advanced HIV disease. AIDS. 11:1997;1405-1406.
3. Apichartpiyakul C., Apichartpiyakul N., Urwijitaroon Y., Gray J., Natpratan C., Katayama Y.et al. Seroprevalence and subtype distribution of hepatitis C virus among blood donars and intravenous drug users in northern/northeastern Thialand. Japanese Journal of Infectious Diseases. 52(3):1999;121-123.
4. Backmund M., Meyer K., Von Zielonka M., Eichenlaub D. Treatment of Hepatitis C infection in injection drug users. Hepatology. 34:2001;188-193.
5. Beilenson, P. L. (1997). Baltimore City 1997 Health status report (pp. 1-16). Maryland: Baltimore City Health Department.
6. Bobkov, A. F., Samokhvalov, E. I., & Lvov, D. K., et al. (2001). Absence of viral transmission in injecting drug users in Russia. Lancet, 22(358, 9286), 1016-1017.
7. Brunton, C., Kemp, R., & Raynel, P., et al., (2000). Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. New Zealand Medical Journal, 24(113, 1106), 98-101.
8. CDC. (1998a). Recommendations for prevention and control of Hepatitis C Virus (HCV) infection and HCV-related chronic disease. MMWR, 47(RR19), 1-39.
9. CDC. (1998b). Hepatitis A among drug abusers. MMWR, 37, 297-300, 305.
10. Celentano D.D., Vlahov D., Cohn S., Shadle V.M., Obasanjo O., Moore R.D. Self-reported antiretroviral therapy in injection drug users. The Journal of American Medical Association. 280(6):1998;544-546.
11. Celentano D.D., Galai N., Sethi A.K., Shah N.G., Strathdee S.A., Vlahov D. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 15(13):2001;1707-1715.
12. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 92(8):1997;999-1005.
13. Davis G.L., Rodrigue J.R. Treatment of chronic hepatitis in active drug users. New England Journal of Medicine. 345(2):2001;215-217.
14. EASL. (1999). EASL International Consensus Conference on Hepatitis C: Paris 26-27 Feb. 1999 consensus statement. Journal of Hepatology, 31(Suppl. 1), 3-8.
15. Edlin B.R., Seal K.H., Lorvick J. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? New England Journal of Medicine. 345(3):2001;211-215.
16. Fried M.W. Diagnostic testing for Hepatitis C: Practical considerations. American Journal of Medicine. 107(6B):1999;31S-35S.
17. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users the prevalence of the hepatitis C, hepatitis B, human immunodeficiency virus, and human T-lymphotropic virus. American Journal of Public Health. 86:1996;655-661.
18. Garfien R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adults injection drug users. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology. 8(S1):1998;S11-S19.
19. Gerberging J. Management of occupational exposure to blood borne virus. New England Journal of Medicine. 332:1995;444-451.
20. Gordon F.D. Cost-Effectiveness of screening patients for hepatitis C. American Journal of Medicine. 107(6B):1999;36S-40S.
21. Grassi L., Mondardini D., Pavanati M.et al. Suicide probability and psychological morbidity secondary to HIV infection: A control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. Journal of Affective Disorders. 64(2/3):2001;195-202.
22. Gretch D.R. Use and interpretation of HCV diagnostic tests in clinical setting. Clinics in Liver Disease. 1:1997;543-557.
23. Gunn R.A., Murray P.J., Ackers M.L.et al. Screening for chronic hepatitis B and C virus infections in urban sexually transmitted disease clinic: Rationale for integrated services. Sexually Transmitted Diseases. 28(3):2001;166-170.
24. Hagan H., McGough J.P., Thiede H. Syringe exchange and risk of infection with hepatitis B and C viruses. American Journal of Epidemiology. 149(3):1999;203-213.
25. Johnson M.E., Fisher D.G., Fenaughty A., Theno S.A. Hepatitis C virus and depression in drug users. American Journal of Gastroenterology. 93(5):1998;785-789.
26. Jowett S.L., Agarwal K., Smith B.C., Craig W., Hewett M., Bassendine D.R.et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM. 94(3):2001;153-158.
27. Knowlton A.R., Hoover D.R., Chung S.E. Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug and Alcohol Dependence. 64(1):2001a;55-62.
28. Knowlton A.R., Latkin C.A., Schroeder J.R. Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care. 13(5):2001b;549-559.
29. Lamden K.H., Kennedy N., Beeching N.J. Hepatitis B and hepatitis C virus infections: Risk factors among drug users in Northwest England. Journal of Infection. 37(3):1998;260-269.
30. Latkin C., Vlahov D., Anthony J.C. Socially desirable response and self-reported HIV infection among intravenous drug users. British Journal of Addiction. 88:1993;517-526.
31. Lauer G.M., Walker B.D. Hepatitis C Virus infection. New England Journal of Medicine. 345(1):2001;41-52.
32. Mansson A.S., Moestrup T., Nordenfelt E., Widell A. Continued transmission of hepatitis B and C viruses but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scandinavian Journal of Infectious Diseases. 32(3):2000;253-258.
33. NIH. (1997). NIH Consensus Statement: Management of Hepatitis C, 15(3), 1-41.
34. O'Connor P.G., Selwyn P.A., Schottenfeld R.S. Medical care for injection-drug users with human immunodeficiency virus infection [Review]. New England Journal of Medicine. 331(7):1994;450-459.
35. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 349(9055):1997;825-832.
36. Rodger A., Roberts S., Lanigan A., Bowden S., Brown T., Crofts N. Assessment of long-term outcomes of community-acquired Hepatitis C infection in a cohort with sera stored from 1971-1975. Hepatology. 32(3):2000;592-597.
37. Smyth B.P., Keenan E., O'Connor J.J. Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. Journal of Epidemiology and Community Health. 53(7):1999;434-435.
38. Strathdee S.A., Palepu A., Cornelisse P.G., Yip B., O'Shaughnessy M.V., Montaner J.S. Barriers to use of free antiretroviral therapy in injection drug users. The Journal of American Medical Association. 280(6):1998;547-549.
39. Stephenson J. Former addicts face barriers to treatment for HCV. The Journal of American Medical Association. 285:2001;1003-1005.
40. Sylvestry, D. (2001). Treating Hepatitis C in recovering injection drug users on methadone [Abstract 2886]. Digestive Disease Week. Atlanta, GA.
41. Sylvestry D.L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 67(2):2002 Jul 1;117-123.
42. Taylor A., Goldberg D., Hutchinson S., Cameron S., Gore S.M., McMenamin J.et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: Are current harm reduction strategies working? Journal of Infection. 40(2):2000;176-183.
43. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfien R.et al. Correlates of hepatitis C virus infection among injection drug users. Medicine. 74:1995;212-220.
44. WHO. (1999). Global surveillance and control of hepatitis C. Journal of Viral Hepatitis, 6, 35-47.
45. Williams I. Epidemiology of hepatitis C in the United States. American Journal of Medicine. 107(6B):1999;2S-9S.
46. Wong J.B. Cost-effectiveness of treatment. American Journal of Medicine. 107(6):1999;74S-78S.
47. van Beek I., Dwyer R., Dore G.J. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. BMJ. 317:1998;433-437.